RA0147

antibody from Oursmab

Targeting: CNR1 CANN6, CB-R, CB1, CB1A, CB1K5, CNR

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0147

Provider

Oursmab

Product name

Nimacimab (Biosimilar Reference Antibody) (CNR1)

Antibody type

Monoclonal

Description

Nimacimab (also known as BMS-986141) is an investigational, human monoclonal antibody that targets the cannabinoid type 1 receptor (CB1R), a G protein-coupled receptor (GPCR) primarily expressed in the central nervous system and peripheral tissues. Unlike small-molecule CB1R antagonists that cross the blood-brain barrier and cause neuropsychiatric side effects, nimacimab is designed to be peripherally restricted¡ªit does not significantly penetrate the central nervous system. By selectively blocking CB1R in peripheral tissues (e.g., liver, adipose tissue, gastrointestinal tract), it aims to modulate metabolic pathways without central adverse effects. It is being developed for the treatment of metabolic disorders, particularly non-alcoholic steatohepatitis (NASH) and obesity-related complications.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.